Azitra, Inc. (AZTR)
| Market Cap | 5.42M |
| Revenue (ttm) | 572,700 |
| Net Income (ttm) | -12.40M |
| Shares Out | 28.80M |
| EPS (ttm) | 0.80 |
| PE Ratio | 0.24 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,709,874 |
| Open | 0.229 |
| Previous Close | 0.216 |
| Day's Range | 0.161 - 0.229 |
| 52-Week Range | 0.161 - 5.180 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 9, 2024 |
About AZTR
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR... [Read more]
Financial Performance
In 2023, Azitra's revenue was $686,000, an increase of 141.55% compared to the previous year's $284,000. Losses were -$12.64 million, -6.02% less than in 2022.
Financial StatementsNews
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced i...
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
Azitra, Inc. Announces Closing of Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, t...
Azitra, Inc. Announces Pricing of Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
Azitra to Present at the ThinkEquity Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today t...
Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRANFORD, Conn., Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, anno...
Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors
BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer
BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces Closing of Initial Public Offering
BRANFORD, Conn. , June 21, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...
Azitra, Inc. Announces Pricing of Initial Public Offering
BRANFORD, Conn. , June 15, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...